Skip to main content
SpringerLink
Log in

Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé)

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

  • Recommandations/Recommendations
  • Published:
Oncologie

Résumé

Contexte

La mise à jour de ces recommandations a été élaborée conjointement par la Fédération nationale des centres de lutte contre le cancer (FNCLCC) en partenariat avec les secteurs public, privé et l’Institut national du cancer.

Objectif

Actualiser les recommandations établies en 2003.

Méthodes

L’actualisation des Standards, Options: Recommandations (SOR) repose sur une revue et une analyse critique des données scientifiques disponibles et sur le jugement argumenté des experts au sein d’un groupe de travail représentatif des modes et lieux d’exercice et des disciplines concernées par la prise en charge des patients atteints de cancer.

Résultats

Cet article présente les recommandations SOR 2008 relatives à la place des traitements complémentaires médicaux de première ligne et de consolidation, établies à l’issue du processus d’actualisation.

Abstract

Context

The Federation of French Comprehensive Cancer Centres (FNCLCC) initiated the update of these recommendations in collaboration with the French National Cancer Institute and specialists from French public universities, general hospitals and private clinics.

Objectives

To update the recommendations established in 2003.

Methods

The guideline up-dating process is based on systematic literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. Consequently, Standards, Options: Recommendations are based on the best available evidence and expert agreement.

Results

This article presents the 2008 updated recommendations concerning medical first-line treatment and consolidation treatment of epithelial ovarian cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. AGREE, AGREE Collaboration (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12: 18–23

    Article  Google Scholar 

  2. Alberts DS, Hannigan EV, Liu PY, et al. (2006) Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol 100: 133–138

    Article  PubMed  CAS  Google Scholar 

  3. Aravantinos G, Fountzilas G, Kosmidis P, et al. (2005) Paclitaxel plus carboplatin versus paclitaxel plus alternating carbo-platin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 16: 1116–1122

    Article  PubMed  CAS  Google Scholar 

  4. Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43

    Article  PubMed  CAS  Google Scholar 

  5. Athavale R, Godfrey K, Deane KHO (2006) The Cochrane collaboration (Protocol). Chemotherapy and/or radiotherapy after surgery fir ovarian carcinosarcoma. Cochrane Database Syst Rev: CD006246

  6. Bell J, Brady MF, Young RC, et al. (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 102: 432–439

    Article  PubMed  CAS  Google Scholar 

  7. Berek JS, Taylor PT, Gordon A, et al. (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507–3516

    Article  PubMed  CAS  Google Scholar 

  8. Bolis G, Danese S, Tateo S, et al. (2006) Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 16(Suppl): 174–178 (2006 January–February)

    Article  Google Scholar 

  9. Chen XY, Wu TX, Liu GJ (2006) The Cochrane collaboration (Protocol). Topotecan for ovarian cancer. The Cochrane database of systematic: CD005589

  10. Clamp AR, Maenpaa J, Cruickshank D, et al. (2006) SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer 94: 55–61

    Article  PubMed  CAS  Google Scholar 

  11. Covens A, Carey M, Bryson P, et al. (2004) CCOPGI Guidelines. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. http://www.cancercare.on.ca/index_gynecologyCancerguidelines.htm

  12. De PS, Scambia G, Di VG, et al. (2004) Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22: 2635–2642

    Article  CAS  Google Scholar 

  13. Du Bois A, Weber B, Rochon J, et al. (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’investigateurs nationaux pour l’étude des cancers ovariens. J Clin Oncol 24: 1127–1135

    Article  PubMed  CAS  Google Scholar 

  14. Elit L, Fyles A, chambers A, et al. (2004) CCOPGI Guidelines. Adjuvant care for stage I ovarian cancer. http://www.cancercare.on.ca/index_gynecology-Cancerguidelines.htm

  15. Elit L, Oliver T, Covens A, et al. (2006) CCOPGI Guidelines. The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. http://www.cancercare.on.ca/index_gynecology-Cancerguidelines.htm

  16. Elit L, Chambers A, Fyles A, et al. (2004) Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 101: 1926–1935

    Article  PubMed  Google Scholar 

  17. Elit L, Oliver TK, Covens A, et al. (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta-analyses. Cancer 109: 692–702

    Article  PubMed  CAS  Google Scholar 

  18. Fervers B, Bonichon F, Demard F, et al. (1995) Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 82: 761–767

    PubMed  CAS  Google Scholar 

  19. Fervers B, Hardy J, Blanc-Vincent MP, et al. (2001) SOR: project methodology. Br J Cancer 84(Suppl 2): 8–16

    Article  PubMed  Google Scholar 

  20. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24: 579–586

    Article  PubMed  CAS  Google Scholar 

  21. Hall GD, Brown JM, Coleman RE, et al. (2004) Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 91: 621–626

    Article  PubMed  CAS  Google Scholar 

  22. Hess LM, Ham-Hutchins M, Herzog TJ, et al. (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17: 561–570

    Article  PubMed  CAS  Google Scholar 

  23. Hirte H, Vergote IB, Jeffrey JR, et al. (2006) A phase III randomized trial of BAY 12-9566 (tranomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102: 300–308

    Article  PubMed  CAS  Google Scholar 

  24. Jaaback K, Johnson N (2006) The Cochrane collaboration (Review). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev: CD005340

  25. Kristensen GB, Vergote I, Stuart G, et al. (2003) First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(Suppl): 2172–2177 (2003 November–December)

    Google Scholar 

  26. Kyrgiou M, Salanti G, Pavlidis N, et al. (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98: 1655–1663

    PubMed  CAS  Google Scholar 

  27. Minagawa Y, Kigawa J, Kanamori Y, et al. (2006) Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol 101: 495–498

    Article  PubMed  CAS  Google Scholar 

  28. Mobus V, Wandt H, Frickhofen N, et al. (2007) Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 25: 418–493

    Article  CAS  Google Scholar 

  29. Morgan RJ Jr., Alvarez RD, Armstrong DK, et al. (2008) Ovarian cancer. Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=l +Agree

  30. Morrison J, Swanton A, Kehoe S (2006) The Cochrane collaboration (Protocol). Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev: CD005343

  31. Nicoletto MO, Tumolo S, Sorio R, et al. (2007) Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. Int J Gynecol Cancer 17: 986–992

    Article  PubMed  CAS  Google Scholar 

  32. Pfisterer J, Weber B, Reuss A, et al. (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98: 1036–1045

    Article  PubMed  CAS  Google Scholar 

  33. Piccart MJ, Floquet A, Scarfone G, et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13(Suppl): 2196–2203 (2003 November–December)

    Google Scholar 

  34. Ray-Coquard I, Paraiso D, Guastalla JP, et al. (2007) Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 97: 1200–1205

    Article  PubMed  CAS  Google Scholar 

  35. Reed NS, Poole CJ, Coleman R, et al. (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 42: 179–185

    Article  PubMed  CAS  Google Scholar 

  36. Sorbe B, Swedish-Norgewian Ovarian Cancer Study Group (2003) Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 13: 278–286

    Article  PubMed  CAS  Google Scholar 

  37. Spriggs DR, Brady MF, Vaccarello L, et al. (2007) Phase III randomized trial of intravenous cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 4466–4471

    Article  PubMed  CAS  Google Scholar 

  38. START (2006) Ovarian cancer. http://www.startoncology.net/capitoli/interno_capitoli/default.jsp?menu=professional&ID=117&language=eng

  39. Vasey PA, Atkinson R, Osborne R, et al. (2006) SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94: 62–68

    Article  PubMed  CAS  Google Scholar 

  40. Vasey PA, Jayson GC, Gordon A, et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682–1691

    PubMed  CAS  Google Scholar 

  41. Verheijen RH, Massuger LF, Benigno BB, et al. (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24: 571–578

    Article  PubMed  CAS  Google Scholar 

  42. Walker JL, Armstrong DK, Huang HQ, et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100: 27–32

    Article  PubMed  Google Scholar 

  43. Wenzel LB, Huang HQ, Armstrong DK, et al. (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437–443

    Article  PubMed  CAS  Google Scholar 

  44. Winter-Roach B, Hooper L, Jayson G, et al. (2006) The Cochrane collaboration (Protocol). Adjuvant (postchirurgical) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev: CD004706

  45. Winter-Roach B, Hooper L, Kitchener H (2003) Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13: 395–404

    Article  PubMed  CAS  Google Scholar 

  46. Young RC, Brady MF, Nieberg RK, et al. (2003) Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group Study. J Clin Oncol 21: 4350–4355

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologue médical (coordinatrice), institut Gustave-Roussy, Villejuif, France

    C. Lhommé

  2. Méthodologiste, chef de projet (FNCLCC), Paris, France

    F. Planchamp

  3. Oncologue médical, centre François-Baclesse, Caen, France

    F. Joly

  4. Centre Oscar-Lambret, Lille, France

    E. Leblanc

  5. Oncologue médical, clinique Mathilde, Rouen, France

    N. Albin

  6. Oncologue médical, centre hospitalier intercommunal, Annemasse, France

    C. Alliot

  7. Oncologue médical, groupe hospitalier La Pitié-Salpêtrière, Paris, France

    G. Auclerc

  8. Oncologue médical, centre hospitalier Jean-Minjoz, Besançon, France

    L. Chaigneau

  9. Oncologue médical, centre Paul-Papin, Angers, France

    R. Delva

  10. Oncologue-radiothérapeute, polyclinique Bordeaux-Nord-Aquitaine, Bordeaux, France

    N. Dohollou

  11. Oncologue médical, hôpital Cochin, Paris, France

    F. Goldwasser

  12. Oncologue médical, centre Henri-Becquerel, Rouen, France

    C. Guillemet

  13. Oncologue médical, hôpital Saint-Louis, Paris, France

    J. -L. Misset

  14. Oncologue médical, centre Léon-Bérard, Lyon, France

    I. Ray-Coquard

  15. Radiothérapeute, centre d’oncologie et de radiothérapie médicale, Arras, France

    H. Rhliouch

  16. Oncologue-radiothérapeute, hôpital Tenon, Paris, France

    E. Touboul

  17. Oncologue médical, hôpital Saint-Antoine, Paris, France

    C. Tournigand

Authors
  1. C. Lhommé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Planchamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Joly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Leblanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Albin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Alliot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Auclerc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Chaigneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Delva
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N. Dohollou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F. Goldwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Guillemet
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. -L. Misset
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H. Rhliouch
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E. Touboul
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. Tournigand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Planchamp.

About this article

Cite this article

Lhommé, C., Planchamp, F., Joly, F. et al. Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé). Oncologie 10, 451–457 (2008). https://doi.org/10.1007/s10269-008-0913-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-008-0913-4

Mots clés

Keywords

Search

Navigation